News & Views

  • Diagnostic Clues Found for PAH
    Dr Talat Nasim

Diagnostic Clues Found for PAH

Mar 25 2019 Read 403 Times

Researchers at the University of Bradford have identified a biomarker that could be used to provide earlier diagnosis for Pulmonary arterial hypertension (PAH), a life limiting condition affecting around 6,500 people in the UK. Caused by a narrowing of the arteries supplying blood to the lungs and leading to possible heart failure, PAH can occur spontaneously at any age.

Led by Dr Talat Nasim, in Bradford’s School of Pharmacy and Medical Sciences and including researchers from the University of Cambridge (UK), Kings College London (UK), University of Dhaka (Bangladesh), Centre for Health Agricultural and Socio-economic Advancements (CHASA, Bangladesh) and Hacettepe University (Turkey), the study* builds on earlier research to investigate the genetic causes of PAH – in particular the mechanism of one faulty gene known as BMPR-II, which was first identified nearly two decades ago.
Dr Nasim explained: “We wanted to find out why the cells are not dying, but instead were building up inside the wall of the pulmonary arteries. To do this, we needed to identify and investigate the proteins that are influenced by this gene.”

The team discovered that the faulty BMPR-II gene affected one particular protein called Bcl-x. This, in turn, is responsible for making two different proteins, one of which increases cell apoptosis and the other one reduces it. These two work in balance in the body to regulate cell death. If BMPR-II is faulty, however, the protein for reducing cell apoptosis is increased – preventing cell death from occurring. “This protein can be used as a biomarker for accurately identifying PAH in patients,” said Dr Nasim. “This could help us diagnose PAH at an earlier stage, possibly leading to better treatment options for patients. We can also make other services available, such as genetic counselling, to help patients understand the disease and to identify those at risk of developing it.”

Dr Nasim’s team has filed a patent for the biomarker and is now investigating whether it could also be a target for new drugs. A number of promising compounds are currently being developed and tested.

*Published in Human Molecular Genetics

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Labmate UK & Ireland September 2019

September 2019

Articles Finding an easy, cost-effective way to break into new markets Exploring safe and intelligent multi-application liquid nitrogen cooling via auto-fill technology Characterisation o...

View all digital editions


16th Confocal Raman Imaging Symposium

Sep 23 2019 Ulm Germany

Analitica Latin America

Sep 24 2019 Sao Paulo, Brazil

Pharma Asia

Sep 24 2019 Karachi, Pakistan


Sep 24 2019 Basel, Switzerland


Sep 25 2019 Bangkok, Thailand

View all events